Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.47 |
| ▸ | JAK1 | P23458 | 9/20 | 0.47 |
| ▸ | TYK2 | P29597 | 9/20 | 0.47 |
| ▸ | RET | P07949 | 10/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 8/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31131686 | 0.87 | RET (0.49) | JAK2JAK1TYK2RETFGFR3 | |
| SCHEMBL19300148 | 0.85 | JAK2 (0.48) | JAK2JAK1TYK2RETFGFR3 | |
| SCHEMBL20401080 | 0.84 | RET (0.41) | JAK2JAK1TYK2RETFGFR3 | |
| SCHEMBL19253538 | 0.82 | JAK2 (0.47) | JAK2JAK1TYK2RETJAK3 | |
| SCHEMBL16427675 | 0.82 | FLT3 (0.49) | JAK2JAK1TYK2RETJAK3 | |
| SCHEMBL20401098 | 0.81 | RET (0.53) | RET | |
| SCHEMBL24439168 | 0.80 | JAK2 (0.47) | JAK2JAK1TYK2RETJAK3 | |
| SCHEMBL19253404 | 0.74 | JAK2 (0.48) | JAK2JAK1TYK2FGFR3KDR | |
| SCHEMBL25192565 | 0.74 | PIM1 (0.45) | JAK2JAK1TYK2RETJAK3 | |
| SCHEMBL25417901 | 0.74 | ALDH1A1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2023-02-09 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | PFIZER INC. (US) | 2022-10-18 | — | — | US | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3954689-A1 | PYRAZOLOPYRAZINE DERIVED COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Primegene (Beijing) Co., Ltd. (CN) | 2022-02-16 | — | — | EP | disclosed |
| EP-3712153-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3712153-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-109071546-B | Pyrazolo [1,5-A ] pyrazin-4-yl derivatives as JAK inhibitors | 辉瑞大药厂 | 2021-03-02 | — | — | CN | disclosed |
| EP-3419978-B1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3419978-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | PFIZER INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129256-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | CBR3, CNR1, CBR1 | JAK2 849/4885JAK1 1320/4885TYK2 1885/4885 |
| US-20230045252-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | JAK2 923/4885JAK1 1401/4885TYK2 1835/4885 |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885TYK2 286/4885 |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | JAK2 923/4885JAK1 1401/4885TYK2 1835/4885 |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | JAK2 923/4885JAK1 1401/4885TYK2 1835/4885 |
| US-11472809-B2 | Pyrazolo[1,5-a]pyrazin-4-yl derivatives | SYMPK, IL15, STAT6 | JAK2 33/4885JAK1 27/4885TYK2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.